These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20970591)

  • 1. Conversion of heart transplant patients from standard to sustained-release tacrolimus requires a dosage increase.
    Marzoa-Rivas R; Paniagua-Martín MJ; Barge-Caballero E; Pedrosa del Moral V; Barge-Caballero G; Grille-Cancela Z; Naya-Leira C; Fariñas-Garrido P; Blanco-Canosa P; Mosquera V; Castro-Beiras A; Crespo-Leiro MG
    Transplant Proc; 2010 Oct; 42(8):2994-6. PubMed ID: 20970591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation.
    Calia R; Lai C; Aceto P; Luciani M; Romagnoli J; Lai S; Gargiulo A; Citterio F
    Transplant Proc; 2011 May; 43(4):1020-3. PubMed ID: 21620041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study.
    Doesch AO; Mueller S; Konstandin M; Celik S; Erbel C; Kristen A; Frankenstein L; Koch A; Dengler TJ; Ehlermann P; Zugck C; De Geest S; Katus HA
    Transplant Proc; 2010 Dec; 42(10):4238-42. PubMed ID: 21168673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus.
    Kurnatowska I; Krawczyk J; Oleksik T; Nowicki M
    Transplant Proc; 2011 Oct; 43(8):2954-6. PubMed ID: 21996199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients.
    Comuzzi C; Lorenzin D; Rossetto A; Faraci MG; Nicolini D; Garelli P; Bresadola V; Toniutto P; Soardo G; Baroni GS; Adani GL; Risaliti A; Baccarani U
    Transplant Proc; 2010 May; 42(4):1320-1. PubMed ID: 20534291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):867-70. PubMed ID: 15848559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation.
    Wente MN; Sauer P; Mehrabi A; Weitz J; Büchler MW; Schmidt J; Schemmer P
    Clin Transplant; 2006; 20 Suppl 17():80-4. PubMed ID: 17100706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors.
    Meçule A; Poli L; Nofroni I; Bachetoni A; Tinti F; Umbro I; Barile M; Berloco PB; Mitterhofer AP
    Transplant Proc; 2010 May; 42(4):1317-9. PubMed ID: 20534290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients.
    Florman S; Alloway R; Kalayoglu M; Punch J; Bak T; Melancon J; Klintmalm G; Busque S; Charlton M; Lake J; Dhadda S; Wisemandle K; Wirth M; Fitzsimmons W; Holman J; First MR
    Transplantation; 2007 Jun; 83(12):1639-42. PubMed ID: 17589349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplantation; 2007 Jun; 83(12):1648-51. PubMed ID: 17589351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First clinical experience with the new once-daily formulation of tacrolimus.
    First MR
    Ther Drug Monit; 2008 Apr; 30(2):159-66. PubMed ID: 18367975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient.
    Merli M; Di Menna S; Giusto M; Giannelli V; Lucidi C; Loria I; Ginanni Corradini S; Mennini G; Rossi M
    Transplant Proc; 2010 May; 42(4):1322-4. PubMed ID: 20534292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation.
    de Jonge H; Kuypers DR; Verbeke K; Vanrenterghem Y
    Transplantation; 2010 Sep; 90(5):523-9. PubMed ID: 20592652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two cases of severe de novo colitis in kidney transplant recipients after conversion to prolonged-release tacrolimus.
    Kurnatowska I; Banasiak M; Daniel P; Wagrowska-Danilewicz M; Nowicki M
    Transpl Int; 2010 May; 23(5):553-8. PubMed ID: 19951264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression.
    Wagner K; Webber SA; Kurland G; Boyle GJ; Miller SA; Cipriani L; Griffith BP; Fricker FJ
    J Heart Lung Transplant; 1997 Mar; 16(3):275-82. PubMed ID: 9087870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of conventional tacrolimus versus prolong release formula as initial therapy in heart transplantation.
    Urbanowicz T; Baszyńska-Wachowiak H; Ligowski M; Straburzyńska-Migaj E; Misterski M; Jemielity M
    Ann Transplant; 2014 Jun; 19():295-9. PubMed ID: 24949728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to tacrolimus extended-release formulation: short-term clinical results.
    Gallego-Valcarce E; Ortega-Cerrato A; Llamas-Fuentes F; Martinez-Fernandez G; Perez-Martinez J; Gomez-Roldan C
    Transplant Proc; 2009; 41(6):2326-7. PubMed ID: 19715909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended release tacrolimus and antiretroviral therapy in a renal transplant recipient: so extended!
    Morelle J; Goffin E; Wallemacq P; De Meyer M; Yombi JC; Mourad M; Kanaan N
    Transpl Int; 2010 Oct; 23(10):1065-7. PubMed ID: 20477995
    [No Abstract]   [Full Text] [Related]  

  • 19. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
    Reitamo S; Harper J; Bos JD; Cambazard F; Bruijnzeel-Koomen C; Valk P; Smith C; Moss C; Dobozy A; Palatsi R;
    Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
    Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.